Imperial College London

ProfessorSimakAli

Faculty of MedicineDepartment of Surgery & Cancer

Professor of Molecular Endocrine Oncology
 
 
 
//

Contact

 

+44 (0)20 7594 2811simak.ali

 
 
//

Location

 

133ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Publication Type
Year
to

151 results found

Buluwela L, Pike J, Mazhar D, Kamalati T, Hart SM, Al-Jehani R, Yahaya H, Patel N, Sarwar N, Heathcote DA, Schwickerath O, Phoenix F, Hill R, Aboagye E, Shousha S, Waxman J, Lemoine NR, Zelent A, Coombes RC, Ali Set al., 2005, Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-alpha and the transcriptional repressor PLZF (vol 12, pg 452, 2005), GENE THERAPY, Vol: 12, Pages: 552-552, ISSN: 0969-7128

Journal article

Buluwela L, Pike J, Mazhar D, Kamalati T, Hart SM, Al-Jehani R, Yahaya H, Patel N, Sarwarl N, Heathcote DA, Schwickerath O, Phoenix F, Hill R, Aboagye E, Shousha S, Waxman J, Lemoine NR, Zelent A, Coombes RC, Ali Set al., 2005, Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-alpha and the transcriptional repressor PLZF, GENE THERAPY, Vol: 12, Pages: 452-460, ISSN: 0969-7128

Journal article

Varshochi R, Halim F, Sunters A, Alao JP, Madureira PA, Hart SM, Ali S, Vigushin DM, Coombes RC, Lam EWFet al., 2005, ICI182,780 induces p21(Waf1) gene transcription through releasing histone deacetylase 1 and estrogen receptor alpha from Sp1 sites to induce cell cycle arrest in MCF-7 breast cancer cell line, JOURNAL OF BIOLOGICAL CHEMISTRY, Vol: 280, Pages: 3185-3196, ISSN: 0021-9258

Journal article

Lucey MJ, Chen DS, Lopez-Garcia J, Hart SM, Phoenix F, Al-Jehani R, Alao JP, White R, Kindle KB, Losson R, Chambon P, Parker MG, Schar P, Heery DM, Buluwela L, Ali Set al., 2005, T : G mismatch-specific thymine-DNA glycosylase (TDG) as a coregulator of transcription interacts with SRC1 family members through a novel tyrosine repeat motif, NUCLEIC ACIDS RESEARCH, Vol: 33, Pages: 6393-6404, ISSN: 0305-1048

Journal article

Alao JP, Lam EWF, Ali S, Buluwela L, Bordogna W, Lockey P, Varshochi R, Stavropoulou AV, Coombes RC, Vigushin DMet al., 2004, Histone deacetylase inhibitor trichostatin a represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines, CLINICAL CANCER RESEARCH, Vol: 10, Pages: 8094-8104, ISSN: 1078-0432

Journal article

Pike J, Holmes D, Kamalati T, Davies D, Tolhurst R, Mazhar D, Fishpool S, al-Jehani R, Waxman J, Zelent A, Lemoine NR, Ali S, Buluwela Let al., 2004, Silencing of androgen-regulated genes using a fusion of AR with the PLZF transcriptional repressor, ONCOGENE, Vol: 23, Pages: 7561-7570, ISSN: 0950-9232

Journal article

HART STEPHEN, ALI SIMAK, PUFONG BORIS T, PORTER ANDREW CG, BULUWELA LAKI, VAINIKKA SATU, JENKINSON JOHN D, KANDA PATRICKet al., 2004, Control of gene expression using a complex of an oligonucleotide and a regulatory peptide

A method for suppressing the expression of a selected gene in a cell the method comprising introducing into the cell a molecule comprising (1) a nucleic acid binding portion which binds to a site or associated with the selected gene which site is present in a genome and (2) an expression repressor portion, wherein the nucleic acid binding portion comprises an oligonucleotide or oligonucleotide mimic or analogue, and wherein the repressor portion comprises a polypeptide or peptidomimetic. Molecules for use in the methods of the invention are provided. The repressor may be a portion of a histone deacetylase or DNA methylase or polypeptide capable of recruiting a histone deacetylase or DNA methylase.

Journal article

Bhat-Nakshatri P, Campbell RA, Patel NM, Newton TR, King AJ, Marshall MS, Ali S, Nakshatri Het al., 2004, Tumour necrosis factor and PI3-kinase control oestrogen receptor alpha protein level and its transrepression function, BRITISH JOURNAL OF CANCER, Vol: 90, Pages: 853-859, ISSN: 0007-0920

Journal article

Vigushin DM, Dong Y, Inman L, Peyvandi N, Alao JP, Sun C, Ali S, Niesor EJ, Bentzen CL, Coombes RCet al., 2004, The nuclear oxysterol receptor LXR alpha is expressed in the normal human breast and in breast cancer, MEDICAL ONCOLOGY, Vol: 21, Pages: 123-131, ISSN: 1357-0560

Journal article

Shou J, Massarweh S, Osborne C K, Wakeling A E, Ali S, Weiss H, Schiff Ret al., 2004, Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer, J Natl Cancer Inst, Vol: 96, Pages: 926-935

Journal article

ALI SIMAK, GARCIA-LOPEZ JORGE, THOMAS ROSS, 2004, ER Inhibitor Peptide

Patent

Buluwela L, Constantinidou D, Pike J, Ali Set al., 2004, Estrogen receptors and anti-estrogen therapies., Cancer Treat Res, Vol: 119, Pages: 271-292, ISSN: 0927-3042

Journal article

SN Lauber, S Ali, NJ Gooderham, 2004, The cooked food derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine is a potent oestrogen: a mechanistic basis for its tissue-specific carcinogenicity., Carcinogenesis, Vol: 25, Pages: 2509-2517

Journal article

Singh A, Ali S, Kothari MS, De Bella MT, Smith C, Timms E, Slade MJ, Foxwell BM, Coombes RCet al., 2003, Reporter gene assay demonstrates functional differences in estrogen receptor activity in purified breast cancer cells: A pilot study, INTERNATIONAL JOURNAL OF CANCER, Vol: 107, Pages: 700-706, ISSN: 0020-7136

Journal article

ALI SIMAK, 2003, METHODS TO MODULATE THE ACTIVITY OF THE OESTROGEN RECEPTOR

Journal article

ALI Simak, 2003, METHODS TO MODULATE THE ACTIVITY OF THE OESTROGEN RECEPTOR

A polypeptide having the amino acid sequence of Seq ID No 1; Figure 1A or an amino acid sequence having at least 45 or 50 % identity with the amino acid sequence of Seq ID No 1 for use in medicine. Use of a compound for modulating, for example a nuclear receptor DNA binding protein, wherein the compound is: (a) the polypeptide ERZFP (SEQ ID No 1; Figure 1A); or, (b) a fragment of the polypeptide ERZPF which binds to the transcription factor, for example a nuclear receptor DNA binding protein; or, (c) a variant of the polypeptide or fragment as defined in (a) or (b) which binds to the transcription factor, for example a nuclear receptor DNA binding protein; or (d) a fusion or derivative of the polypeptide or fragment as defined in (a), (b) or (c) which binds to the transcription factor, for example a nuclear receptor DNA binding protein; or (e) a peptidomimetic of the polypeptide, fragment, variant, fusion or derivative as defined in (a), (b), (c), or (d) which binds to the transcription factor, for example a nuclear receptor DNA binding protein; or, (f) a compound, for example an antibody or antibody fragment which mimics the binding of the polypeptide, fragment, variant, fusion or derivative as defined in (a), (b), (c), or (d) to the transcription factor, for example a nuclear receptor DNA binding protein. A method for identifying a compound which modulates, for example promotes the transcription factor activity of a transcription factor, for example a nuclear receptor DNA binding protein, comprising the steps of: (a) providing the transcription factor, for example a nuclear receptor DNA binding protein or a fragment thereof comprising the AF1 domain for fragment thereof, and a compound as defined above; (b) exposing a test compound to the transcription factor, for example a nuclear receptor DNA binding protein or fragment and/or a compound as defined above; (c) determining whether the test compound modulates, for example inhibits, the ability of the transcription

Journal article

Chen DS, Lucey MJ, Phoenix F, Lopez-Garcia J, Hart SM, Losson R, Buluwela L, Coombes RC, Chambon P, Schar P, Ali Set al., 2003, T : G mismatch-specific thymine-DNA glycosylase potentiates transcription of estrogen-regulated genes through direct interaction with estrogen receptor alpha, JOURNAL OF BIOLOGICAL CHEMISTRY, Vol: 278, Pages: 38586-38592, ISSN: 0021-9258

Journal article

Martin LA, Farmer I, Johnston SRD, Ali S, Marshall C, Dowsett Met al., 2003, Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation, JOURNAL OF BIOLOGICAL CHEMISTRY, Vol: 278, Pages: 30458-30468, ISSN: 0021-9258

Journal article

Kothari MS, Ali S, Buluwela L, Livni N, Shousha S, Sinnett HD, Vashisht R, Thorpe P, Van Noorden S, Coombes RC, Slade MJet al., 2003, Purified malignant mammary epithelial cells maintain hormone responsiveness in culture, British Journal of Cancer, Vol: 88, Pages: 1071-1076, ISSN: 1532-1827

Currently, the therapy for breast cancer is determined by immunohistochemical staining of the primary tumour for oestrogen receptor alpha (ERα). However, a proportion of ERα-positive patients fail to respond to tamoxifen and a proportion of ERα-negative patients show response. Here, we describe a novel procedure for the purification of malignant breast epithelial cells in an attempt to identify these patients at an early stage. Using this procedure, we are able to purify malignant cells to >90% purity as determined by immunohistochemical staining, cytology and fluorescent in situ hybridisation (FISH). While the malignant cells can be maintained in culture they do not proliferate in contrast to purified breast epithelial cells from reduction mammoplasties. Moreover, ERα and progesterone receptor (PR) expression is maintained in malignant cells, whereas normal epithelial cells rapidly lose ERα and PR. Functional studies were performed on the separated malignant cells in terms of their response to oestradiol and tamoxifen. Four out of the seven ERα-positive tumours showed a significant reduction in cell numbers after tamoxifen treatment compared to oestradiol, ERα negative tumours failed to show a response. We conclude that (a) it is possible to purify and maintain breast cancer cells for a sufficient period to permit functional studies and (b) ERα is retained in culture facilitating the use of these cells in studies of the mechanism of endocrine response and resistance in vitro.

Journal article

Simak Ali, Laki Buluwela, David Holmes, Tahereh Kamalati, Jonathan Waxmanet al., 2003, Silencing of endogenous gene expression, WO03010308

Patent

VAINIKKA SATU, HART STEPHEN, ALI SIMAK, PUFONG BORIS TUMI, PORTER ANDREW CHRISTOPHER GEOR, BULUWELA LAKI, JENKINSON JOHN DAVID, KANDA PATRICKet al., 2002,

Journal article

HART STEPHEN, ALI SIMAK, PUFONG BORIS, PORTER ANDREW CHRISTOPHER GEOR, BULUWELA LAKI, VAINIKKA SATUet al., 2002,

Journal article

HART STEPHEN, ALI SIMAK, PUFONG BORIS TUMI, PORTER ANDREW CHRISTOPHER, BULUWELA LAKI, VAINIKKA SATU, JENKINSON JOHN DAVID, KANDA PATRICKet al., 2002,

Journal article

HART STEPHEN, ALI SIMAK, PUFONG BORIS TUMI, PORTER ANDREW CHRISTOPHER GEORGE, BULUWELA LAKI, VAINIKKA SATU, JENKINSON JOHN DAVID, KANDA PATRICKet al., 2002, CONTROL OF GENE EXPRESSION USING A COMPLEX OF AN OLIGONUCLEOTIDE AND A REGULATORY PEPTIDE

A method for suppressing the expression of a selected gene in a cell the method comprising introducing into the cell a molecule comprising (1) a nucleic acid binding portion which binds to a site or associated with the selected gene which site is present in a genome and (2) an expression repressor portion, wherein the nucleic acid binding portion comprises an oligonucleotide or oligonucleotide mimic or analogue, and wherein the repressor portion comprises a polypeptide or peptidomimetic. Molecules for use in the methods of the invention are provided. The repressor may be a portion of a histone deacetylase or DNA methylase or polypeptide capable of recruiting a histone deacetylase or DNA methylase.

Journal article

HART STEPHEN, ALI SIMAK, PUFONG BORIS, PORTER ANDREW, BULUWELA LAKI, VAINIKKA SATU, JENKINSON JOHN, KANDA PATRICKet al., 2002,

Journal article

Chan CMW, Martin LA, Johnston SRD, Ali S, Dowsett Met al., 2002, Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation, JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, Vol: 81, Pages: 333-341, ISSN: 0960-0760

Journal article

Chen DS, Washbrook E, Sarwar N, Bates GJ, Pace PE, Thirunuvakkarasu V, Taylor J, Epstein RJ, Fuller-Pace FV, Egly JM, Coombes RC, Ali Set al., 2002, Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera, ONCOGENE, Vol: 21, Pages: 4921-4931, ISSN: 0950-9232

Journal article

BULUWELA LAKJAYA, HOLMES DAVID, KAMALATI TAHEREH, WAXMAN JONATHAN, ALI SIMAKet al., 2002, CONTROL OF GENE EXPRESSION

A method of suppressing the expression of a selected endogenous gene in a eukaryotic cell the method comprising introducing into the cell (a) a polypeptide comprising a nucleic acid binding portion which binds to a site at or associated with the selected gene and a modifying portion which comprises a polypeptide or peptidomimetic which is capable of modulating covalent modification of nucleic acid or chromatin, for example a chromatin inactivation portion, or (b) a polynucleotide encoding said polypeptide. The binding of the molecule to nucleic acid may be modulated by a ligand and the molecule may comprise a ligand binding portion. The nucleic acid binding portion may be a nucleic acid binding portion of a nuclear receptor DNA binding protein.

Journal article

Ali S, Coombes RC, 2002, Endocrine-responsive breast cancer and strategies for combating resistance, NATURE REVIEWS CANCER, Vol: 2, Pages: 101-+, ISSN: 1474-175X

Journal article

Ali S, Coombes RC, 2002, Endocrine responsive breast cancer and strategies for combating resistance, Nat Rev Cancer, Vol: 2, Pages: 101-112, ISSN: 1474-175X

Journal article

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: id=00165709&limit=30&person=true&page=4&respub-action=search.html